ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the achievement of $100 million in milestones from Incyte Corporation related to development progress of ZYNYZ® (retifanlimab-dlwr), following an agreement on July 24, 2024, pursuant to which certain milestones were deemed to have been met. ZYNYZ ...

ROCKVILLE, MD, July 30, 2024 (GLOBE NEWSWIRE) --  MacroGenics, Inc. (NASDAQ:MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced the achievement of $100 million in milestones from Incyte Corporation related to development progress of ZYNYZ® (retifanlimab-dlwr), following an agreement on July 24, 2024, pursuant to which certain milestones were deemed to have been met. ZYNYZ ...

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against MacroGenics, Inc. (“MacroGenics” or “the Company”) (NASDAQ: MGNX) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired MacroGen ...

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of MacroGenics, Inc. (NASDAQ: MGNX). Shareholders who purchased shares of MGNX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/macrogenics-inc-loss-submission-form-2/?id=92722&from=3 CLASS PERIOD: March 7, 2 ...

文章核心观点 - 该文章报道了针对MacroGenics公司的集体诉讼,指控该公司在披露其抗体偶联药物MGC018(vobra duo)在转移性去势抵抗性前列腺癌(mCRPC)患者中的TAMARACK II期临床试验数据时存在误导性陈述 [1][3] - 公司在2024年3月7日表示,由于剂量降低和给药频率降低,预计安全性会有所改善,可能会达到或超过之前3mg/kg每3周的疗效 [4] - 公司在2024年4月3日公布了TAMARACK试验的初步安全性数据,称剂量和给药频率降低可改善vobra duo的安全性和耐受性 [5] - 但在2024年5月10日,公司披露有5名患者在试验中死亡,导致股价大跌约77% [6][7] - 公司表示正在调查3名患者死亡的原因,但尚未向投资者提供更新 [8] 公司相关 - MacroGenics公司是一家生物制药公司,专注于开发抗体偶联药物 [1][3] - 公司的主要产品之一是抗体偶联药物MGC018(vobra duo),正在进行mCRPC患者的II期临床试验TAMARACK [3][4][5] - 公司在2024年3月和4月就TAMARACK试验的初步数据做出了积极表述,但后来却出现了5名患者死亡的情况 [4][5][6][7] 行业相关 - 该文章涉及生物制药行业,特别是抗体偶联药物在前列腺癌治疗领域的临床开发 [3][4][5] - 临床试验数据的披露和解读是生物制药公司面临的重要挑战之一,可能会对公司股价产生重大影响 [6][7]

SAN DIEGO, July 29, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers of MacroGenics, Inc. (NASDAQ: MGNX) stock or sellers of MacroGenics puts between March 7, 2024 and May 9, 2024, inclusive (the “Class Period”), have until September 24, 2024 to seek appointment as lead plaintiff of the MacroGenics class action lawsuit. Captioned Crain v. MacroGenics, Inc., No. 24-cv-02184 (D. Md.), the MacroGenics class action lawsuit charges MacroGenics and MacroGenics’ Chief Executive O ...

NEW YORK, July 29, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased the stock or sold puts of MacroGenics, Inc. (“MacroGenics”) (NASDAQ: MGNX) between March 7, 2024 and May 9, 2024, inclusive (the “Class Period”). For more information, submit a form at MacroGenics, Inc. Shareholder Class Action Lawsuit, email Investor Relations Manager Peter Allocco at pallocco@bernlieb.com, or call us ...

ATLANTA, July 29, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Macrogenics, Inc. (“MGNX” or the “Company”) (NASDAQ: MGNX). The lawsuit alleges that Defendants provided investors with material information concerning MGNX’s early interim safety data from MGNX’s ongoing TAMARACK Phase 2 study of vobramitamab duocarmazine (vobra duo) in patients with metastatic astration – resistant prostate cancer (mCRPC) that materially mislead and/or failed to disclose information pertin ...

BOSTON, July 29, 2024 (GLOBE NEWSWIRE) -- Block & Leviton announces that a securities fraud lawsuit has been filed against MacroGenics, Inc. (NASDAQ: MGNX) and certain of its executives. Investors who have lost money in their MacroGenics investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://blockleviton.com/cases/mgnx. What is this all about? The lawsuit alleges that MacroGenics and its executives made material misrepresentations about th ...

NEW YORK, July 26, 2024 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX) between March 7, 2024 to May 9, 2024, both dates inclusive. You are hereby notified that the class action lawsuit Derek Crain v. MacroGenics, Inc., et al. (Case No. 8:24-cv-02184) has been commenced in the United States District Court for the District of Ma ...